Taylor Graham W, Gilbertson Janet A, Sayed Rabya, Blanco Angel, Rendell Nigel B, Rowczenio Dorota, Rezk Tamer, Mangione P Patrizia, Canetti Diana, Bass Paul, Hawkins Philip N, Gillmore Julian D
National Amyloidosis Centre and Wolfson Drug Discovery Unit, Centre for Amyloidosis and Acute Phase Proteins, University College London, London, UK.
Centre for Nephrology, Division of Medicine, Royal Free Campus, University College London, London, UK.
Kidney Int Rep. 2019 Apr 15;4(7):977-986. doi: 10.1016/j.ekir.2019.04.007. eCollection 2019 Jul.
Hereditary fibrinogen Aα-chain (AFib) amyloidosis is a relatively uncommon renal disease associated with a small number of pathogenic fibrinogen Aα (FibA) variants; wild-type FibA normally does not result in amyloid deposition. Proteomics is now routinely used to identify the amyloid type in clinical samples, and we report here our algorithm for identification of FibA in amyloid.
Proteomics data from 1001 Congo red-positive patient samples were examined using the Mascot search engine to interrogate the Swiss-Prot database and generate protein identity scores. An algorithm was applied to identify FibA as the amyloid protein based on Mascot scores. FibA variants were identified by appending the known amyloidogenic variant sequences to the Swiss-Prot database.
AFib amyloid was identified by proteomics in 64 renal samples based on the Mascot scores relative to other amyloid proteins, the presence of a pathogenic variant, and coverage of the p.449-621 sequence. Contamination by blood could be excluded from a comparison of the FibA score with that of the fibrinogen β and γ chains. The proteomics results were consistent with the clinical diagnosis. Four additional renal samples did not fulfill all the criteria using the algorithm but were adjudged as AFib amyloid based on a full assessment of the clinical and biochemical results.
AFib amyloid can be identified reliably in glomerular amyloid by proteomics using a score-based algorithm. Proteomics data should be used as a guide to AFib diagnosis, with the results considered together with all available clinical and laboratory information.
遗传性纤维蛋白原Aα链(AFib)淀粉样变性是一种相对罕见的肾脏疾病,与少数致病性纤维蛋白原Aα(FibA)变体相关;野生型FibA通常不会导致淀粉样蛋白沉积。蛋白质组学现在常用于识别临床样本中的淀粉样蛋白类型,我们在此报告我们用于识别淀粉样蛋白中FibA的算法。
使用Mascot搜索引擎检查来自1001例刚果红阳性患者样本的蛋白质组学数据,以查询瑞士蛋白质数据库并生成蛋白质识别分数。应用一种算法根据Mascot分数将FibA识别为淀粉样蛋白。通过将已知的淀粉样变性变体序列附加到瑞士蛋白质数据库中来识别FibA变体。
基于相对于其他淀粉样蛋白的Mascot分数、致病性变体的存在以及p.449-621序列的覆盖范围,通过蛋白质组学在64个肾脏样本中鉴定出AFib淀粉样变性。通过比较FibA分数与纤维蛋白原β链和γ链的分数,可以排除血液污染。蛋白质组学结果与临床诊断一致。另外四个肾脏样本未满足该算法的所有标准,但根据对临床和生化结果的全面评估被判定为AFib淀粉样变性。
使用基于分数的算法,通过蛋白质组学可以在肾小球淀粉样变性中可靠地鉴定出AFib淀粉样变性。蛋白质组学数据应用作AFib诊断的指南,其结果应与所有可用的临床和实验室信息一起考虑。